Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Palatin Technologies Inc PTN

Healthcare Biotechnology

Palatin Technologies, Inc. is a biopharmaceutical company. The Company is engaged in developing medicines based on molecules that modulate the activity of the melanocortin receptor system. The Company’s product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with unmet medical needs and commercial potential. Its new product development activities focus... see more

Add To Watchlist

Recent & Breaking News (NYSEAM:PTN)

Palatin Technologies, Inc. Announces Completion of Enrollment of Phase 2 Study with PL9643 for the Treatment of Dry Eye Disease

PR Newswire August 5, 2020

Palatin Technologies Announces Mutual Termination of License Agreement with AMAG Pharmaceuticals for Vyleesi®

PR Newswire July 27, 2020

Palatin Technologies, Inc. Announces Reinitiation of Enrollment of Phase 2 Study with PL9643 for the Treatment of Dry Eye Disease

PR Newswire July 8, 2020

Palatin Technologies Announces Adjournment of Annual Meeting of Stockholders

PR Newswire June 29, 2020

Palatin Technologies to Develop PL8177 as a Potential Treatment for COVID-19 and Associated Lung Complications

PR Newswire June 23, 2020

Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2020 Financial Results and Recent Business Highlights

PR Newswire May 12, 2020

Palatin Technologies, Inc. to Report Third Quarter Fiscal Year 2020 Results; Teleconference and Webcast to be held on May 12, 2020

PR Newswire May 7, 2020

Palatin Technologies Provides Assessment of Impact of COVID-19 Pandemic on Business Operations

PR Newswire April 30, 2020

Palatin Technologies, Inc. Announces First Patient Enrolled in Dry Eye Disease Phase 2 Clinical Trial with PL9643

PR Newswire February 19, 2020

Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2020 Financial Results and Recent Business Highlights

PR Newswire February 11, 2020

Palatin Technologies, Inc. to Report Second Quarter Fiscal Year 2020 Results; Teleconference and Webcast to be held on February 11, 2020

PR Newswire February 6, 2020

Palatin Provides Corporate Update and 2020 Calendar Outlook

PR Newswire January 21, 2020

Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2020 Results and Provides Corporate Update

PR Newswire November 13, 2019

Palatin Presents On Pl8177 Oral Colon Delivery Formulation For Ulcerative Colitis At The 7Th CPC Symposium On Peptide Therapeutics

PR Newswire October 17, 2019

Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year 2019 Results

PR Newswire September 12, 2019

Palatin Technologies, Inc. to Report Fourth Quarter & Fiscal Year End 2019 Results; Teleconference and Webcast to be held on September 12, 2019

PR Newswire September 11, 2019

Palatin Technologies To Present At Canaccord Genuity's 39th Annual Growth Conference

PR Newswire August 6, 2019

Palatin Technologies Provides Mid-Calendar Year Corporate Update

PR Newswire July 1, 2019

FDA Approves New Drug Application for Vyleesi(TM) (bremelanotide injection)

PR Newswire June 21, 2019

Palatin Technologies Granted FDA Orphan Drug Designation -- PL-8177 for the Treatment of Non-Infectious Uveitis

PR Newswire June 6, 2019